Lexeo Therapeutics Inc

LXEO

Company Profile

  • Business description

    Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.

  • Contact

    345 Park Avenue South
    Floor 6
    New YorkNY10010
    USA

    T: +1 212 547-9879

    https://www.lexeotx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    75

Stocks News & Analysis

stocks

Nvidia: Collaboration with Intel might bring some goodwill with the US

We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.
stocks

What now for Santos after takeover offer collapses?

Our Fair Value estimate once again reflects the stand-alone business and its growth potential.
stocks

Morningstar initiates coverage on small cap ASX REIT

Coverage of ASX listed REIT as investor interest in property continues to grow.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,061.2020.50-0.23%
CAC 407,853.591.02-0.01%
DAX 4023,639.4135.12-0.15%
Dow JONES (US)46,287.23144.810.31%
FTSE 1009,216.6711.44-0.12%
HKSE26,545.100.250.00%
NASDAQ22,571.17100.450.45%
Nikkei 22545,045.81257.62-0.57%
NZX 50 Index13,231.66111.630.85%
S&P 5006,652.4320.470.31%
S&P/ASX 2008,773.5018.70-0.21%
SSE Composite Index3,820.0911.57-0.30%

Market Movers